[go: up one dir, main page]

AR022229A1 - Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion - Google Patents

Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion

Info

Publication number
AR022229A1
AR022229A1 ARP000100079A ARP000100079A AR022229A1 AR 022229 A1 AR022229 A1 AR 022229A1 AR P000100079 A ARP000100079 A AR P000100079A AR P000100079 A ARP000100079 A AR P000100079A AR 022229 A1 AR022229 A1 AR 022229A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
phenyl
optionally substituted
aromatic
Prior art date
Application number
ARP000100079A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR022229A1 publication Critical patent/AR022229A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de triazol de la Formula general (1) en donde: R1 representa H, alquilo C1-6, sustituido opcionalmente por OH, alquilo OC1-6, halogeno o fenilo,cicloalquilo C3-6 o fenilo; R2 representa H, alquilo C1-6, sustituido opcionalmente por OH,alq uilo OC1-6, halogeno o fenilo, alcoxi C1-6, alquiltio C1-6,alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, halogeno, CN, COOR3, CONR3R4, NR3R4, SO2R3, SO2NR3R', o un resto aromático, seleccionado entre fenilo,naftilo y un resto heterocíclicode 5 o 6 miembros con 1, 2, 3 o 4 heteroátomos, seleccionados independientemente uno de otro entre O, N y S, pudiendopresentar el resto aromático uno o dos sustituyentes, seleccionados independientemente uno de otro entre alquilo C1-6, sustituidoopcional mente por OH, alquiloOC1-6, halogeno o fenilo, alcoxi C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, halogeno, CN, COR3, NR3R4, NO2, SO2R3, SO2NR3R4 y fenilo, sustituidoopcionalmente por uno o dos restos seleccionadosindependientemente uno de otro entre alquilo C1-6, alcoxi C1-6, NR3R4, CN, CF3, CHF2 o halogeno; R3 y R4representan independientemente uno de otro H, alquilo C1-6 sustituido opcionalmente por OH, alquilo OC1-6, halogeno o fenilo, o fenilo; Arepresenta alquilenoC4-10 o al quileno C3-10, que comprende por lo menos un grupo Z, seleccionado entre O, S, CONR3, COO, CO, cicloalquilo C3-6 y un enlace doble o triple; Bsignifica un resto de la formula (2) en donde: X representa CH2 o CH2CH2;R6, R7 y R8 seleccionados independ ientemente uno de otro entre H, alquilo C1-6opcionalmente sustituido por OH, alquilo OC1-6 opcionalmente sustituido por amino, mono- o di-alquilamino C1-4, alquiltio C1-6, halogeno o fenilo; OH, alcoxiC1-6, OCF3,OSO2CF3, SH, alquiltio C1-6, alquenil o C2-6, alquinilo C2-6, halogeno, CN, NO2, CO2R3, SO2R3, SO2NR3R4, en donde R3 y R4 tienen el significadoarriba mencionado y junto con el átomo de N, al cual están ligados, pueden formar también un heterociclosaturado o no saturado con 5-7 miembros del anillo y 1o 2 heteroátomos N; CONR3R4, NHSO2R3, NR3R4, un anillo aromático o no aromático carbocíclico de 5 o 6 miembros y un anillo aromático o no aromático
ARP000100079A 1999-01-12 2000-01-10 Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion AR022229A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12

Publications (1)

Publication Number Publication Date
AR022229A1 true AR022229A1 (es) 2002-09-04

Family

ID=7894006

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP000100079A AR022229A1 (es) 1999-01-12 2000-01-10 Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
ARP000100080A AR022230A1 (es) 1999-01-12 2000-01-10 Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
ARP000100078A AR022228A1 (es) 1999-01-12 2000-01-10 Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP000100080A AR022230A1 (es) 1999-01-12 2000-01-10 Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
ARP000100078A AR022228A1 (es) 1999-01-12 2000-01-10 Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion

Country Status (28)

Country Link
US (3) US6602867B1 (es)
EP (3) EP1144405B1 (es)
JP (3) JP2002534521A (es)
KR (3) KR100775720B1 (es)
CN (3) CN1149209C (es)
AR (3) AR022229A1 (es)
AT (3) ATE366729T1 (es)
AU (3) AU2289700A (es)
BG (2) BG65086B1 (es)
BR (2) BR0007504A (es)
CA (3) CA2359948C (es)
CO (3) CO5150224A1 (es)
CZ (2) CZ303926B6 (es)
DE (3) DE50015802D1 (es)
ES (2) ES2334326T3 (es)
HK (1) HK1045311B (es)
HR (1) HRP20010590A2 (es)
HU (2) HUP0200522A3 (es)
ID (2) ID29552A (es)
IL (3) IL144137A0 (es)
NO (2) NO20013444D0 (es)
NZ (2) NZ512830A (es)
PL (2) PL200238B1 (es)
SK (2) SK9852001A3 (es)
TR (2) TR200102026T2 (es)
TW (1) TWI274750B (es)
WO (3) WO2000042036A1 (es)
ZA (2) ZA200106584B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
ES2255311T3 (es) 1998-10-08 2006-06-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de los receptores d3 de dopamina (agentes anti-psicoticos).
AR022229A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
EP1283199A4 (en) * 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd MELANINE CONCENTRATING HORMONE ANTAGONISTS
HUP0302264A2 (hu) 2000-11-14 2003-11-28 Smithkline Beecham P.L.C. Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
EP1456178A1 (en) * 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
DE10304870A1 (de) 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
ES2308157T3 (es) * 2003-03-17 2008-12-01 Bayer Healthcare Ag Disgnosticos y tratamientos para enfermedades asociadas con el receptor de la dopamina d3 (drd3).
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EP1687299A1 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treamtment and/or prevention of disorders modulated by a ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
BRPI0507945A (pt) 2004-02-23 2007-07-24 Glaxo Group Ltd derivados de azabiciclo (3.1.0) hexano utilizáveis como moduladores de receptores d3 de dopamina
WO2005087764A1 (en) * 2004-03-08 2005-09-22 Glaxo Group Limited Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents)
WO2005090320A2 (en) * 2004-03-12 2005-09-29 Wyeth Triazole derivatives and method of using the same to treat hiv infections
GB0412314D0 (en) * 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
JP4904267B2 (ja) * 2004-08-09 2012-03-28 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
WO2006058753A1 (en) 2004-12-02 2006-06-08 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine d3 receptor
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
US7807698B2 (en) 2005-06-14 2010-10-05 Glaxo Group Limited Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
CA2677481C (en) 2007-02-08 2015-07-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
CN102264733B (zh) 2008-10-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
ES2523766T3 (es) * 2009-12-22 2014-12-01 Cephalon, Inc Hexahidrocromeno[3,4-b]pirroles sustituidos con afinidad por la familia de los receptores de serotonina (5-HT)
JPWO2012124744A1 (ja) * 2011-03-14 2014-07-24 大正製薬株式会社 含窒素縮合複素環化合物
PE20142366A1 (es) * 2012-05-30 2015-01-10 Hoffmann La Roche Compuestos triazolo como inhibidores de pde 10
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
EP3189041B1 (en) 2014-09-03 2021-04-28 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
EP3634406B1 (en) * 2017-05-12 2023-09-06 Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
WO1992020655A1 (en) 1991-05-20 1992-11-26 The Upjohn Company Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
ES2164054T3 (es) 1991-11-05 2002-02-16 Smithkline Beecham Corp Antagonistas de receptores de endotelina.
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
SK130595A3 (en) 1993-04-27 1996-06-05 Smithkline Beecham Corp New indane and indene derivatives, preparing method, pharmaceutical compositions containing them and their use
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
CN1088062C (zh) * 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
WO1996030333A1 (en) 1995-03-27 1996-10-03 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
WO1996031512A1 (en) 1995-04-06 1996-10-10 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
AU7490496A (en) * 1995-11-10 1997-05-29 Novo Nordisk A/S Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
FR2742149B1 (fr) 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
ES2191838T3 (es) * 1996-05-11 2003-09-16 Smithkline Beecham Plc Derivados de tetrahidroisoquinoleina como moduladores de los receptores d3 de la dopamina.
CA2255612A1 (en) * 1996-05-31 1997-12-04 Pharmacia & Upjohn Company Aryl substituted cyclic amines as selective dopamine d3 ligands
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
ES2154470T3 (es) 1996-08-14 2001-04-01 Smithkline Beecham Plc Derivados de tetrahidroisoquinolina y su uso farmaceutico.
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
DK0942911T3 (da) 1996-12-06 2002-12-02 Abbott Lab Benzopyranopyrroler og benzopyranopyridiner med alfa-1-adrenerg virkning
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
IL132631A0 (en) * 1997-05-03 2001-03-19 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022229A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion

Also Published As

Publication number Publication date
HUP0200709A3 (en) 2004-07-28
NO20013444L (no) 2001-07-11
AU773047B2 (en) 2004-05-13
DE50015576D1 (de) 2009-04-16
AR022230A1 (es) 2002-09-04
EP1140908A1 (de) 2001-10-10
IL144136A (en) 2006-12-10
BG105784A (en) 2002-02-28
HUP0200522A3 (en) 2003-05-28
EP1144405B1 (de) 2009-11-25
CZ20012551A3 (cs) 2002-03-13
KR100775720B1 (ko) 2007-11-09
HUP0200709A2 (hu) 2002-07-29
SK9852001A3 (en) 2002-04-04
IL144136A0 (en) 2002-05-23
HK1045311A1 (en) 2002-11-22
JP4933694B2 (ja) 2012-05-16
AU772948B2 (en) 2004-05-13
AR022228A1 (es) 2002-09-04
NO20013444D0 (no) 2001-07-11
PL201889B1 (pl) 2009-05-29
NO20013443D0 (no) 2001-07-11
ATE366729T1 (de) 2007-08-15
TR200102025T2 (tr) 2002-05-21
WO2000042036A1 (de) 2000-07-20
US6579892B1 (en) 2003-06-17
PL200238B1 (pl) 2008-12-31
EP1140907A1 (de) 2001-10-10
WO2000042037A1 (de) 2000-07-20
PL350246A1 (en) 2002-12-02
TR200102026T2 (tr) 2001-12-21
BR0007504A (pt) 2001-10-02
CN1347414A (zh) 2002-05-01
CO5150227A1 (es) 2002-04-29
CN1149209C (zh) 2004-05-12
CO5150182A1 (es) 2002-04-29
CN1345318A (zh) 2002-04-17
HRP20010590A2 (en) 2003-08-31
CA2359948C (en) 2010-09-21
US6583166B1 (en) 2003-06-24
IL144137A0 (en) 2002-05-23
EP1140908B1 (de) 2009-03-04
NZ512830A (en) 2003-08-29
ZA200106584B (en) 2002-08-12
JP4615125B2 (ja) 2011-01-19
CZ303926B6 (cs) 2013-06-26
DE50015802D1 (de) 2010-01-07
AU2289700A (en) 2000-08-01
JP2002534520A (ja) 2002-10-15
PL349841A1 (en) 2002-09-23
BR0007500A (pt) 2001-10-23
KR100730667B1 (ko) 2007-06-21
CA2359952A1 (en) 2000-07-20
JP2002534519A (ja) 2002-10-15
HK1045311B (zh) 2007-03-30
CA2359942A1 (en) 2000-07-20
DE50014472D1 (de) 2007-08-23
SK9862001A3 (en) 2002-04-04
ZA200106585B (en) 2002-08-12
EP1140907B1 (de) 2007-07-11
ATE424398T1 (de) 2009-03-15
NO20013443L (no) 2001-07-12
AU2436700A (en) 2000-08-01
TWI274750B (en) 2007-03-01
CA2359948A1 (en) 2000-07-20
ES2288839T3 (es) 2008-02-01
KR100687682B1 (ko) 2007-02-28
ID29930A (id) 2001-10-25
KR20070032830A (ko) 2007-03-22
BG105783A (en) 2002-03-29
BG65086B1 (bg) 2007-02-28
WO2000042038A1 (de) 2000-07-20
EP1144405A1 (de) 2001-10-17
KR20010086471A (ko) 2001-09-12
ES2334326T3 (es) 2010-03-09
HUP0200522A2 (en) 2002-06-29
CO5150224A1 (es) 2002-04-29
BG65105B1 (bg) 2007-02-28
NZ512864A (en) 2003-04-29
ID29552A (id) 2001-09-06
CN1345319A (zh) 2002-04-17
ATE449768T1 (de) 2009-12-15
CZ20012550A3 (cs) 2002-02-13
US6602867B1 (en) 2003-08-05
CN1267430C (zh) 2006-08-02
KR20010086470A (ko) 2001-09-12
AU2541200A (en) 2000-08-01
JP2002534521A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
AR022229A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
AR012488A1 (es) Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion
AR035933A1 (es) Un compuesto derivado de fosfonato nucleosido aciclico, uso del mismo, un proceso para su preparacion y un compuesto de fosfonato.
EA200001122A1 (ru) Ингибиторы синтазы оксида азота
PT1263724E (pt) Novos compostos
RU94040390A (ru) Производные виниленазаиндола, способ их получения, фармацевтическая композиция
AR032165A1 (es) Carboxamidas heterociclicas, composiciones farmaceuticas, uso de dichas carboxamidas para preparar un medicamento como agentes antivirales y el uso in vitro para inhibir una dna polimerasa viral
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
RU2012140961A (ru) ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
EA200400054A1 (ru) Замещенные нафтилиндольные производные в качестве ингибиторов ингибитора активатора плазминогена типа 1 (pai-1)
RU2007110629A (ru) Ингибиторы днк-пк
AR015449A1 (es) Derivados piperidil- o peperazinil-dihidro sustituidos-2h-1-benzopirano composicion farmaceutica que los contiene, su uso para la elaboracion de unmedicamento, procedimiento para su preparacion y compuesto intermediario para su exclusivo uso en dicho procedimiento
AR036472A1 (es) Derivados de azetidina, procedimientos para su preparacion y su empleo como agentes pesticidas
ES2157524T3 (es) Diselenuros y selenosulfuros utilizables como agentes antioxidantes.
NO20000737D0 (no) Tetrahydro <gamma>-karboliner
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
ES2064341T3 (es) Nuevas n-(3-hidroxi-4-piperidinil)benzamidas sustituidas.
AR012157A1 (es) Derivados de piridina, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados.
AR036074A1 (es) Derivados de aminoquinolina, las composiciones farmaceuticas que los contienen, el uso de los mismos para la preparacion de una composicion farmaceutica, un procedimiento para su preparacion y los intermediarios empleados en dicho procedimiento de preparacion
AR045939A1 (es) Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
PA8444901A1 (es) Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
RU2001114213A (ru) Циклоалкилзамещенное производное аминометилпирролидина
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
AR031808A1 (es) 2-piridonas antimicrobianas, sus composiciones y usos
MX9300306A (es) Bencimidazoles medicamentos que contienen estos compuestos y procedimiento para su preparacion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal